CMR shows that anthracycline cardiotoxicity is common in women treated for early breast cancer and associated with undiagnosed hypertension; but cannot be reliably detected using late-gadolinium enhancement imaging by Paul Kotwinski et al.
POSTER PRESENTATION Open Access
CMR shows that anthracycline cardiotoxicity
is common in women treated for early breast
cancer and associated with undiagnosed
hypertension; but cannot be reliably detected
using late-gadolinium enhancement imaging
Paul Kotwinski1,2*, Gillian Smith1, Julie Sanders1, Jackie Cooper4, David Kotwinski1, Albert Teis2,
Michael (Monty) G Mythen5, Alison Jones3, Hugh E Montgomery1, Dudley J Pennell2
From 16th Annual SCMR Scientific Sessions
San Francisco, CA, USA. 31 January - 3 February 2013
Background
A growing number of patients with cancer are at risk from
chronic anthracycline cardiotoxicity (cAC) as a result of
improving cancer prognosis. Although susceptibility is
cumulative dose-related, it is also idiosyncratic. Further-
more, at present there is no way to reliably identify those
at risk. The common practice of serially measuring LV
ejection fraction (LVEF) only identifies cardiotoxicity after
significant damage has been incurred. We hypothesised
that risk of cAC could be determined from patient and
treatment factors, known at baseline, together with assess-
ment of the cardiac response to the 1st dose of anthracy-
cline. Here we report the prevalence of cAC detected
using CMR, together with the associations with baseline
BP and anthracycline dose.
Methods
Women due to receive anthracycline-based chemotherapy
for early breast cancer were recruited. Those with known
cardiovascular disease were excluded. CMR was per-
formed on Siemens 1.5T scanners before chemotherapy
and at follow-up (>1 year after the final anthracycline
cycle, and >3 months after Trastuzumab). LVEF was mea-
sured from cine images by a single operator (PK) blind to
clinical and temporal data, using CMRtools. Chronic AC
(cAC) was defined as a fall in absolute LVEF ≥5%.
Results
164 subjects completed the study 18.5 [15.1-23.7] months
after finishing treatment. 99% received epirubicin (400
[300-450] mg/m2). The mean fall in LVEF was 2.2%
(p<0.001), compared with a projected increase of 0.2%.
The cardiac response was heterogeneous: 20.7% (N=34)
were in the subclinical cAC group. Mean LVEF also fell in
the remainder of the cohort (by 0.8%, p=0.03), demon-
strating this group were minimally affected, rather than
unaffected. No subjects developed late gadolinium
enhancement as a result of treatment (LGE images in
N=119). There was a trend towards patients who received
epirubicin ≥450mg/m2 being in the cAC group (odds ratio
(OR) 2.12 [0.97-4.60], p=0.06). Patients with baseline BP
≥140/90mmg were more likely to be in the cAC group
(OR 3.63 [1.31-10.09], p=0.01); of these 18, only 1 was
diagnosed and treated for hypertension.
Conclusions
Falls in LVEF ≥5% were detected in >20% of patients.
Declines in resting LVEF are relatively late in the patholo-
gical process of cAC and therefore likely to reflect
increased risk of heart failure as a ‘late-effect’ of cancer
treatment. Our data suggest that undiagnosed hyperten-
sion was common; diagnosing and treating it may offer an
opportunity to reduce cAC. A fall in LVEF ≥5% detected
by CMR may be a better end-point for monitoring
cardiotoxicity in oncology trials than those currently used.
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and ex-vivo data, it cannot be reliably detected using LGE;
T1-mapping may be of greater utility.
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